Browse the evidence

For individuals with obesity and prediabetes who fail to achieve early weight loss (<2.5% at 4 weeks), adding exercise counseling or time-restricted eating (TRE) counseling does not significantly improve weight loss or glycemic outcomes compared to continuing the initial diet alone.

If you are not losing weight in the first month of a diet, simply adding more exercise counseling or trying a new eating window might not be enough. You may need more intensive support, such as provided meals or supervised exercise, rather than just advice.

Senescent cells secrete a complex, heterogeneous proteome (SASP) that includes specific proteins (GDF15, STC1, SERPINs) which correlate with human aging and serve as potential plasma biomarkers for cellular senescence burden.

This research identifies specific proteins (GDF15, STC1, SERPINs) secreted by senescent cells that correlate with aging in human blood. While not yet a commercial test, these markers offer a potential way to measure 'senescent burden' in the future, linking cellular aging to systemic health.

Grip strength is not significantly associated with prostate cancer mortality, although it is associated with the incidence of prostate cancer.

For men, low grip strength does not predict death from prostate cancer. However, it is associated with a higher *incidence* of prostate cancer, possibly because stronger men are more health-conscious and get screened more often. Do not use grip strength to rule out prostate cancer risk.

Intake of total fat, saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), and polyunsaturated fatty acids (PUFA) is not associated with the risk of cardiovascular disease.

Current evidence from this meta-analysis does not support limiting total fat, saturated fat, or monounsaturated fat intake to prevent CVD, as no association was found. Focus on avoiding trans fats instead.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) improve glycemic control in type 2 diabetes by blocking glucose reabsorption in the renal proximal tubule, inducing glycosuria.

If you have Type 2 Diabetes and your kidneys are functioning adequately (eGFR > 30), SGLT2 inhibitors like empagliflozin or dapagliflozin can help lower your blood sugar by causing your kidneys to excrete glucose in your urine. This is done via a daily oral pill. While there is a risk of genital infections, they are generally mild and manageable. The key benefit is that these drugs also offer cardiovascular and renal protection beyond just lowering blood sugar.

Once-weekly subcutaneous dulaglutide (1.5 mg) is administered to patients with type 2 diabetes to evaluate its effect on cardiovascular outcomes, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

This paper outlines the design of the REWIND trial, which tests whether once-weekly dulaglutide (1.5 mg) reduces cardiovascular events (heart attack, stroke, cardiovascular death) in people with type 2 diabetes who are at high risk. The trial includes nearly 10,000 participants with a mean age of 66, many of whom have prior cardiovascular disease or risk factors. The results of this trial will help determine if dulaglutide is an effective cardiovascular protective agent for this population.

Intramuscular androgen receptor content, rather than systemic or intramuscular hormone levels, determines the magnitude of resistance training-induced skeletal muscle hypertrophy in healthy, young men.

If you are a healthy, young man who already lifts weights regularly, your muscle growth potential is likely determined by your genetic muscle receptor density, not your blood testosterone levels. You cannot change your receptor density with supplements or TRT if your levels are already normal. Focus on consistent, progressive resistance training rather than trying to manipulate hormones.

Obesity pathophysiology is driven by complex interactions between genetic susceptibility, environmental factors, and hormonal signaling (leptin, insulin, ghrelin, GLP-1) that regulate energy balance, rather than simple caloric imbalance alone.

Obesity is not just a failure of willpower; it involves complex hormonal signals (like leptin and insulin) and genetics. Effective management often requires addressing these biological drivers, potentially through lifestyle changes combined with medical therapies that target these specific pathways.

Changes in specific health behaviors (physical activity, diet composition, alcohol, smoking) were not consistently associated with diabetes remission in this study.

While weight loss is crucial, simply trying to change your diet or exercise habits without focusing on the resulting weight loss may not be enough to put diabetes into remission. The weight loss itself is the key factor.

High body mass index (BMI) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. Excess body weight forces your kidneys to work harder (hyperfiltration), which can cause long-term damage. While weight loss is complex in advanced kidney disease, preventing obesity is a primary strategy for avoiding kidney failure.

Semaglutide 2.4 mg once weekly does not increase the risk of developing symptoms of depression or suicidal ideation/behavior compared to placebo in people with overweight or obesity without known major psychopathology.

If you are considering semaglutide for weight loss and are worried about your mental health, know that large clinical trials show it does not increase the risk of depression or suicidal thoughts compared to a placebo. While you should still monitor your mood as recommended, the medication itself is not causing these psychiatric issues. This is particularly reassuring if you have no history of major mental health conditions.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, glomerular hypertension, and adipose-derived inflammatory mediators, independent of diabetes and hypertension.

Maintaining a healthy body weight is critical for kidney health. Obesity increases pressure inside the kidney's filtering units (glomeruli) and releases hormones that cause inflammation and scarring, leading to chronic kidney disease. This risk exists even if you do not have diabetes or high blood pressure. Preventing obesity through lifestyle changes is the most effective way to protect your kidneys.

Replacing saturated fatty acids (SFAs) with carbohydrates does not significantly alter coronary heart disease (CHD) incidence, indicating that the specific macronutrient substitution of SFA for carbohydrate is not a primary driver of CHD risk in isolation.

Do not assume that simply swapping saturated fats for carbohydrates will lower your risk of heart disease. This study suggests that the macronutrient swap itself has no significant effect on CHD incidence. Instead, focus on the quality and source of the foods you eat.

GLP-1 RAs can cause clinically significant drug-drug interactions (DDIs) by delaying gastric emptying, particularly affecting the absorption of oral contraceptives and levothyroxine.

If you take oral contraceptives or levothyroxine, be aware that GLP-1 drugs can change how well these work by slowing stomach emptying. Your doctor may need to monitor your levels or adjust doses. Use backup contraception if advised.

Initiation of modern antiretroviral therapy (ART), specifically integrase strand transfer inhibitors (INSTIs) like dolutegravir and bictegravir combined with tenofovir alafenamide (TAF), causes significant, sustained weight gain in people living with HIV, disproportionately affecting women and Black patients.

If you are living with HIV and starting or taking modern medication (specifically drugs ending in '-gravir' like dolutegravir or bictegravir, and TAF), expect significant weight gain, especially if you are a woman or Black. This is not just 'getting older' or 'eating too much'; it is a known side effect of the medication's interaction with your metabolism. Talk to your doctor about your risk factors. They may consider regimens with TDF (which mitigates weight gain) or other alternatives, though these may have other side effects. Be aware that standard diet and exercise might be less effective for this specific type of gain, and emerging weight-loss medications might be considered in the future.

Integrase strand transfer inhibitors (INSTIs), particularly dolutegravir and bictegravir, are the primary drivers of weight gain in modern ART regimens, with effects observed as early as 4 weeks post-initiation.

If you are taking an INSTI (like dolutegravir or bictegravir), be aware that these drugs are strongly linked to weight gain, often starting within weeks of taking them. This is a known side effect of the drug class, not just your lifestyle. If you are at high risk (e.g., woman, Black patient), discuss your concerns with your doctor. They might consider alternative regimens, though these may have other trade-offs.

Caffeine does not significantly enhance upper-body muscle endurance (bench press repetitions) at any tested dose (2, 4, or 6 mg/kg).

If you are doing single-set upper-body endurance tests (like bench press to failure at 60% 1RM), caffeine is unlikely to help you perform more repetitions, regardless of the dose. This contrasts with lower-body endurance, where caffeine is effective.

When subcutaneous white adipose tissue (scWAT) reaches its maximal storage capacity, it becomes dysfunctional and fails to store lipids appropriately, leading to ectopic fat accumulation in the liver and visceral depots, thereby causing non-alcoholic fatty liver disease (NAFLD).

If you are obese, your body's ability to store fat safely in your subcutaneous areas (like thighs and arms) may be maxed out. Once this 'buffer' is full, excess fat spills over into your liver and visceral organs, causing disease. Strategies to improve metabolic health should focus on preventing this overflow, potentially through interventions that support adipose tissue health or reduce caloric intake to match storage capacity.

Biomarker-based personalized nutrition plans do not result in greater weight loss or improvements in cardiometabolic health compared to a generic, generally healthy diet in individuals with overweight or obesity.

If you have overweight or obesity, following a generally healthy, balanced diet that provides enough food to satisfy you will result in similar weight loss and health improvements as following a highly personalized, biomarker-driven diet plan. You do not need to undergo expensive metabolic testing or follow complex personalized rules to achieve significant health benefits; consistency with a healthy, isocaloric diet is sufficient.

GLP-1 monotherapy (liraglutide, semaglutide) is associated with high discontinuation rates due to gastrointestinal side effects, limiting long-term adherence.

Be aware that GLP-1 monotherapy can cause significant gastrointestinal side effects, leading to high discontinuation rates. Discuss titration strategies with your provider to minimize these effects.

GLP-1 receptor activation suppresses glucagon secretion primarily through an indirect mechanism involving somatostatin release from delta-cells, rather than direct action on alpha-cells.

GLP-1 drugs help control blood sugar not just by boosting insulin, but by suppressing glucagon (a hormone that raises blood sugar). This suppression happens indirectly by stimulating other cells (delta-cells) to release somatostatin, which then inhibits glucagon. This dual action makes GLP-1 drugs effective for lowering blood glucose.

Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.

Hunger isn't just an empty stomach; it's a biological signal that boosts your brain's reward system for food. This is why cravings feel so compelling. Understanding this biological drive can help separate the feeling of hunger from the act of eating.

GLP-1 receptor agonists directly modulate immune cell function, specifically suppressing T-cell activity and pro-inflammatory cytokine release, independent of metabolic changes.

GLP-1 medicines interact directly with your immune system. They can dampen the activity of T cells, which are key drivers of inflammation. This direct interaction helps reduce the production of inflammatory markers like TNF-α and IL-2, contributing to overall health benefits beyond blood sugar control.

GLP-1 receptor agonists reduce cardiovascular events and atherosclerosis progression through weight-loss-independent anti-inflammatory mechanisms involving endothelial and immune cell modulation.

GLP-1 medications like semaglutide and liraglutide are proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with type 2 diabetes and obesity. This protection is partly due to direct anti-inflammatory effects on blood vessels, independent of weight loss. These benefits are significant enough to be a primary reason for prescribing these drugs in high-risk patients.